DS Healthcare's drive for hair-thinning category gets nod of approval from investment world

By Simon Pitman

- Last updated on GMT

DS Healthcare's drive for hair-thinning category gets nod of approval from investment world
The recent announcement that DS Healthcare is entering the market for hair-thinning treatments has been met with approval from one industry analyst.

Sharon di Stefano, a contributor to the financial investment digital title Seeking Alpha, believes the company is making a move with a promising-looking product, at the right time.

“A head of healthy hair denotes confidence which leads to success and no company knows this better than DS Healthcare,”​ states di Stefano.

She compares the launch of the product and the research around it to competition such as Propecia, which she claims is a ‘bad drug’, due to side effects that are said to include swelling of break tissue, weight gain and impotence.

DS Healthcare hair-thinning patent could prove highly valuable

DS Healthcare holds a composition patent for the technology behind its new hair thinning treatment, which comes in the form of a tablet, and is only the third such patent to be registered in the US.

The other patents are held by Johnson & Johnson for its Rogaine, a product that has had limited success on the market, together with the patent for the Propecia technology.

Di Stefano also points to the fact that DS Healthcare’s vision extends to geographic expansion, with plans well under way to increase distribution through North and South America, as well as plans to expand into the China market.

Oral hair-thinning product to be launched in Mexico

Florida-based DS Healthcare says it will use Mexico to platform the launch of the new oral product targeting the multi-billion-dollar hair-loss category.

Marketed under the company’s DS Laboratories brand name, the product marks a new departure for the business, which has traditionally focused on topical skin care and hair care products.

But besides the fact that it is an oral product that will be marketed as a nutraceutical, the company is also claiming that clinical trials have proved it to be more effective, when compared to similar products on the market.

Complex peptides and antioxidants

Although the full details of the formulation are not being disclosed, the company says that its development team has focused on a combination of complex peptides and antioxidants that serve to enhance the efficacy and potency of the product.

Initially the line will be launched in Mexico, during the first quarter of 2014, before being expanded into other major markets worldwide.

Currently the company markets a range of topical therapies and personal care products in 15 countries worldwide, but it is hoping that with the success of it DS Healthcare hair-thinning tablet, it will be able to expand that footprint.

Related topics Business & Financial

Related news

Show more